Bristol-Myers Squibb ( BMY) is a global biopharmaceutical Company, which is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products. Dividend Yield: 4.01% Rated "A+ (Buy)" by TheStreet Ratings: Bristol-Myer Squibb's gross profit margin for the first quarter of its fiscal year 2012 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. Bristol-Myers Squibb has average liquidity. Currently, the Quick Ratio is 1.01 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow. At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 2.11% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.